Abstract
Hematopoietic stem cell transplantation is the treatment of choice for severe primary T-cell immunodeficiencies. When an HLA-identical sibling as the donor is not available, an alternative donor stem cell source is needed. In primary T-cell immunodeficiencies, T-cell-depleted HLA-haploidentical bone marrow transplantation has been particularly successful in reconstituting the immune system in many but not all of the severe T-cell immune deficiency disorders. This study reports the use of umbilical cord blood (UCB) stem cell transplantation in severe T-cell immune deficiency.
Umbilical cord blood was evaluated as a stem cell source for immune reconstitution in children with severe primary T-cell immunodeficiency disorders, such as severe combined immunodeficiency syndrome (SCID), reticular dysgenesis, thymic dysplasia, combined immunodeficiency disease (CID), and Wiskott–Aldrich syndrome (WAS) when a matched sibling donor was unavailable. From 1/96 through 5/98, eight children received unrelated cord blood stem cell transplantation following a preparative regimen for the treatment of combined immunodeficiency diseases. The patients ranged in age from 2 weeks to 8 years. The cord blood units were 3/6 HLA antigen matches in two children, 4/6 in four children, and 5/6 in two child, with molecular HLA-DR mismatch in three of the children. The average time for neutrophil engraftment (absolute neutrophil count >500/mm3) was 12 days (range 10–15 days) and the average time for platelet engraftment (platelet count >20,000/mm3) was 36 days (range 24–50 days). A patient with reticular dysgenesis failed to engraft following her first transplant, but fully engrafted after a second unrelated donor cord blood transplantation. Five of six patients exhibited grade I graft-versus-host disease (GvHD), while one child had grade IV skin and gut GvHD. Immunologic reconstitution demonstrated that cord blood stem cell transplantation resulted in consistent and stable T-, B- and natural killer (NK) cell development. The kinetics of development were such that T-cell development occurred between 60 to 100 days. Initial T-cell engraftment consisted predominantly of CD45RO+, CD3+, and CD4+ T cells, and at 12 to 24 months changed to CD45RA+, CD3+, and CD4+ T cells, indicatingde novomaturation of T cells. NK cell development occurred at approximately 180 days. B cells engrafted early, and study of functional B-cell antibody responses revealed that five of six patients in whom intravenous immune globulin has been discontinued have low detectable antibody responses to tetanus and diphtheria toxoid immunizations at 18 to 24 months posttransplantation.
Unrelated umbilical donor cord blood is an alternative source of stem cells for transplantation in children with severe T-cell immune deficiency disorders when a suitable HLA-matched donor is not available and when a T-depleted haploidentical preparation is not beneficial. Benefits of UCB include rapid and reliable recovery of immune function, low risk of GvHD, and low viral transmission rate.
Similar content being viewed by others
REFERENCES
O'Reilly RJ, Friedrich W, Small TN: Transplantation approaches for severe combined immunodeficiency disease, Wiskott-Aldrich syndrome, and other lethal genetic, combined immunodeficiency disorders. In Bone Marrow Transplantation SJ Forman, KG Blume, ED Thomas (eds). Boston, Blackwell Scientific Publications, 1994, pp 849-867
O'Marcaigh AS, Cowan MJ: Bone marrow transplantation for inherited diseases. Curr Opin Oncol 9:126-130, 1997
Buckley RH, Schiff RI, Schiff SE, et al.: Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 130:378-387, 1997
Fischer A, Landais P, Friedrich W, et al.: Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other that severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodefciency. Blood 83:1149-1154, 1994
Stephan JL, Vlekova V, Le Deist F, et al.: Severe combined immunodeficiency: A retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 123:564-572, 1993
O'Reilly RJ, Keever CA, Small TN, Brochstein J: The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. Immunodefic Rev 1:273-309, 1989
Dickinson AM, Reid MM, Abinun M, et al.: In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID). Bone Marrow Transplant 19:323-329, 1997
Haddad E, Le Deist F, Aucouturier P, et al.: Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: A singlecenter study of 22 patients. Blood 94:2923-2930, 1999
Gluckman E, Broxmeyer HE, Auerbach AD, et al.: Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 321:1174-1178, 1989
Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE: Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 346:214-219, 1995
Kurtzberg J, Laughlin M, Graham ML, et al.: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335:157-166, 1996
Cairo MS, Wagner JE: Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood 90:4665-4678, 1997
Wagner JE, Kurtzberg J: Cord blood stem cells. Curr Opin Hematol 4:413-418, 1997
Gluckman E, Rocha V, Boyer-Chammard A, et al.: Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 337:373-381, 1997
Knutsen AP, Wall D: Kinetics of T-cell development of umbilical cord blood stem transplantation in severe T cell immunodeficiency disorders. J Allergy Clin 103:823-832, 1999
Rubinstein P, Dobrila L, Rosenfield RE, et al.: Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 92:10119-10122, 1995
Mayani H, Lansdorp PM: Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 16:153-165, 1998
Balduzzi A, Gooley T, Anasetti C, et al.: Unrelated donor marrow transplantation in children. Blood 86:3247-3256, 1995
Fischer A, Landais P, Friedrich W, et al.: European experience of bone-marrow transplantation for severe combined immunodefi-ciency. Lancet 336:850-854, 1990
Will AM: Umbilical cord blood transplantation. Arch Dis Child 80:3-6, 1999
Lang P, Handgretinger R, Schumm M, et al.: Transplantation of purified peripheral CD34+ stem cells from unrelated donors in children: Effective prevention of GVHD. Blood 94(Suppl. 1):667a, 1999
Comans-Bitter W, de Groot R, van den Beernd R, et al.: Immunophenotyping of blood lymphocytes in childhood: Reference values for lymphocyte subpopulations. J Pediatr 130:388-393, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Knutsen, A.P., Wall, D.A. Umbilical Cord Blood Transplantation in Severe T-Cell Immunodeficiency Disorders: Two-Year Experience. J Clin Immunol 20, 466–476 (2000). https://doi.org/10.1023/A:1026463900925
Issue Date:
DOI: https://doi.org/10.1023/A:1026463900925